Each capsule contains 222mg of fenbendazole. Our “Broad-Spectrum Anthelmintic” formulation provides a potent, single-dose option for effective parasitic control, leveraging fenbendazole’s established efficacy against a wide array of helminths and protozoa while minimizing dosing frequency for greater convenience and compliance in treatment regimens. Fenbendazole, a benzimidazole anthelmintic agent, exerts its therapeutic effects primarily by selectively binding to β-tubulin in parasitic cells, disrupting microtubule polymerization and leading to impaired glucose uptake, glycogen depletion, and subsequent breakdown of cellular integrity and function, resulting in anthelmintic activity without significant impact on mammalian hosts due to lower binding affinity in human tubulin. This mechanism also extends to potential anticancer applications by destabilizing microtubules in tumor cells, activating the p53 tumor suppressor pathway, inhibiting GLUT1 glucose transporters and hexokinase activity to starve cancer metabolism, and modulating multiple cellular pathways for apoptosis induction, showing preclinical promise in reducing tumor growth and metastasis in models of colorectal, lung, and lymphoma cancers while its broad antiparasitic spectrum covers roundworms, hookworms, whipworms, Taenia species, and Giardia for comprehensive management of gastrointestinal and systemic infections. Fenbendazole is also being investigated off-label for anti-cancer properties in humans, with anecdotal reports from protocols like Joe Tippens’ and emerging preclinical data supporting its role in integrative oncology, though clinical trials are urgently needed to validate efficacy and safety.